Cholangiocarcinoma

Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.

Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.

Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.

The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.

Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.

Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.

A keynote highlighting genomic profiling in the management of patients with intrahepatic cholangiocarcinoma.

Retrospective analysis data indicate that adjuvant chemoradiotherapy was associated with improved survival compared with chemotherapy alone in patients with extrahepatic CCA.